Edap Tms (NASDAQ:EDAP) issued its earnings results on Wednesday. The medical equipment provider reported $0.01 EPS for the quarter, meeting analysts’ consensus estimates of $0.01, Morningstar.com reports. Edap Tms had a positive return on equity of 2.51% and a negative net margin of 0.93%. The business had revenue of $11.50 million during the quarter, compared to analyst estimates of $13.25 million.

EDAP traded down $0.77 during midday trading on Thursday, reaching $3.78. 3,292 shares of the company were exchanged, compared to its average volume of 197,238. The company has a debt-to-equity ratio of 0.09, a quick ratio of 1.97 and a current ratio of 2.40. The firm has a market capitalization of $129.62 million, a P/E ratio of 190.00 and a beta of 1.90. Edap Tms has a one year low of $1.35 and a one year high of $5.42.

Institutional investors and hedge funds have recently modified their holdings of the business. Naples Global Advisors LLC bought a new stake in Edap Tms during the 4th quarter worth approximately $31,000. Commonwealth Equity Services LLC increased its holdings in Edap Tms by 27.0% during the 1st quarter. Commonwealth Equity Services LLC now owns 23,500 shares of the medical equipment provider’s stock worth $70,000 after purchasing an additional 5,000 shares in the last quarter. Hilton Capital Management LLC bought a new stake in Edap Tms during the 1st quarter worth approximately $75,000. Finally, Fosun International Ltd increased its holdings in Edap Tms by 46.0% during the 4th quarter. Fosun International Ltd now owns 249,143 shares of the medical equipment provider’s stock worth $421,000 after purchasing an additional 78,516 shares in the last quarter. 10.07% of the stock is owned by hedge funds and other institutional investors.

A number of analysts recently commented on EDAP shares. TheStreet raised Edap Tms from a “c” rating to a “b-” rating in a research report on Wednesday, May 8th. ValuEngine lowered Edap Tms from a “strong-buy” rating to a “buy” rating in a report on Thursday, April 18th. HC Wainwright reissued a “buy” rating and set a $6.50 price objective on shares of Edap Tms in a report on Wednesday, April 3rd. Finally, Zacks Investment Research lowered Edap Tms from a “buy” rating to a “hold” rating in a report on Wednesday, January 16th.

TRADEMARK VIOLATION NOTICE: This piece of content was published by Marea Informative and is the property of of Marea Informative. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of United States and international copyright law. The correct version of this piece of content can be read at https://www.mareainformativa.com/news/2019/05/16/edap-tms-edap-issues-earnings-results-meets-expectations.html.

Edap Tms Company Profile

EDAP TMS SA, together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally-invasive medical devices for the treatment of urological diseases worldwide. The company operates in two divisions: High Intensity Focused Ultrasound (HIFU), and Urology Devices and Services (UDS).

See Also: What is insider trading?

Earnings History for Edap Tms (NASDAQ:EDAP)

Receive News & Ratings for Edap Tms Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edap Tms and related companies with MarketBeat.com's FREE daily email newsletter.